Derrick Katayama

Principal Scientist, Legacy BioDesign

Derrick Katayama, Ph.D. is the Principal Scientist at Legacy BioDesign, LLC. Dr. Katayama received his Ph.D. in Pharmaceutical Sciences from the University of Colorado Health Sciences Center (UCHSC) with studies focused on understanding protein stability in both liquid and lyophilized forms. Dr. Katayama has worked in the biopharmaceutical industry for over 10 years, prior to joining Legacy BioDesign, LLC. He has experience working on peptide and protein formulation at Amylin Pharmaceuticals Inc., with formulation and characterization of protein subunit vaccine candidates at MedImmune Inc., and at Boehringer Ingelheim in Fremont, CA, participating in the Analytical and Formulation Development group responsible for formulation development of monoclonal antibodies.